Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Common Equity: 2010-2025

Historic Common Equity for Ironwood Pharmaceuticals (IRWD) over the last 15 years, with Sep 2025 value amounting to -$264.2 million.

  • Ironwood Pharmaceuticals' Common Equity rose 15.15% to -$264.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$264.2 million, marking a year-over-year increase of 15.15%. This contributed to the annual value of -$301.3 million for FY2024, which is 12.98% up from last year.
  • Ironwood Pharmaceuticals' Common Equity amounted to -$264.2 million in Q3 2025, which was up 14.28% from -$308.2 million recorded in Q2 2025.
  • Ironwood Pharmaceuticals' 5-year Common Equity high stood at $706.9 million for Q1 2023, and its period low was -$346.8 million during Q2 2023.
  • Moreover, its 3-year median value for Common Equity was -$321.7 million (2024), whereas its average is -$225.7 million.
  • Its Common Equity has fluctuated over the past 5 years, first skyrocketed by 9,722.85% in 2021, then tumbled by 165.08% in 2023.
  • Over the past 5 years, Ironwood Pharmaceuticals' Common Equity (Quarterly) stood at $605.9 million in 2021, then rose by 7.67% to $652.4 million in 2022, then plummeted by 153.08% to -$346.3 million in 2023, then increased by 12.98% to -$301.3 million in 2024, then grew by 15.15% to -$264.2 million in 2025.
  • Its Common Equity stands at -$264.2 million for Q3 2025, versus -$308.2 million for Q2 2025 and -$334.1 million for Q1 2025.